In pan-gliomas and LGGs from TCGA dataset, disease-specific survival (DSS), overall survival (OS), and progression-free interval (PFI) of patients with high B2M were significantly shorter than those with low B2M (Fig. 2A,B). The gene discussed is B2M; the disease is central nervous system cancer.